Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
clinical trials
fda
indiana blog main
indiana top stories
life sciences
national blog main
new york blog main
4
×
new york top stories
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
national top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
calcitonin gene-related peptide
eptinezumab
erenumab
fremanezumab
galcanezumab
migraine research foundation
national
teva pharmaceutical
aimmune therapeutics
alder biopharmaceutical
What
approval
4
×
drug
fda
4
×
won
class
developed
migraine
new
oral
agency
aimmune
allergy
amgen
approved
arguments
awarded
bid
big
boehringer
candidates
commercialized
companies
competitors
decades
diabetes
drugs
eli
expand
fallen
friday
gets
head
immunotherapy
ingelheim
late
lilly
make
marketed
medicines
medicine’s
Language
unset
Current search:
approval
×
fda
×
" new york blog main "
×
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines